(HELX) Franklin Genomic - Ratings and Ratios
Exchange: BATS • Country: USA • Currency: USD • Type: Etf • ISIN: US35473P5200 • Health
HELX: Genomics, Healthcare, DNA, Medicine, Technology, Biotech, Science
Under normal market conditions, the fund invests at least 80% of its net assets in equity securities of companies that are relevant to its investment theme of genomic advancements. The fund invests predominantly in common stock. Although it may invest across economic sectors, the fund concentrates its investments in health care related industries. It is non-diversified.
Additional Sources for HELX ETF
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
HELX ETF Overview
| Market Cap in USD | 13m |
| Category | Health |
| TER | 0.50% |
| IPO / Inception | 2020-02-25 |
HELX ETF Ratings
| Growth 5y | -5.77% |
| Fundamental | - |
| Dividend | 6.0% |
| Rel. Strength Industry | -97.2 |
| Analysts | - |
| Fair Price Momentum | 26.81 USD |
| Fair Price DCF | - |
HELX Dividends
| Dividend Yield 12m | 0.00% |
| Yield on Cost 5y | % |
| Annual Growth 5y | -100.00% |
| Payout Consistency | 20.0% |
HELX Growth Ratios
| Growth Correlation 3m | -60.6% |
| Growth Correlation 12m | -23.9% |
| Growth Correlation 5y | -40.9% |
| CAGR 5y | 5.02% |
| CAGR/Mean DD 5y | 0.16 |
| Sharpe Ratio 12m | -0.10 |
| Alpha | -27.48 |
| Beta | 1.07 |
| Volatility | 22.76% |
| Current Volume | 5.3k |
| Average Volume 20d | 7.9k |
What is the price of HELX stocks?
As of January 23, 2025, the stock is trading at USD 30.34 with a total of 5,300 shares traded.
Over the past week, the price has changed by +3.30%, over one month by +3.32%, over three months by -3.65% and over the past year by +0.75%.
As of January 23, 2025, the stock is trading at USD 30.34 with a total of 5,300 shares traded.
Over the past week, the price has changed by +3.30%, over one month by +3.32%, over three months by -3.65% and over the past year by +0.75%.
Is Franklin Genomic a good stock to buy?
Neither. Based on ValueRay Analyses, Franklin Genomic is currently (January 2025) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of -5.77 and therefor a technical neutral rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of HELX as of January 2025 is 26.81. This means that HELX is currently overvalued and has a potential downside of -11.63%.
Neither. Based on ValueRay Analyses, Franklin Genomic is currently (January 2025) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of -5.77 and therefor a technical neutral rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of HELX as of January 2025 is 26.81. This means that HELX is currently overvalued and has a potential downside of -11.63%.
Is HELX a buy, sell or hold?
Franklin Genomic has no consensus analysts rating.
Franklin Genomic has no consensus analysts rating.
What are the forecast for HELX stock price target?
According to ValueRays Forecast Model, HELX Franklin Genomic will be worth about 29.9 in January 2026. The stock is currently trading at 30.34. This means that the stock has a potential downside of -1.52%.
According to ValueRays Forecast Model, HELX Franklin Genomic will be worth about 29.9 in January 2026. The stock is currently trading at 30.34. This means that the stock has a potential downside of -1.52%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 29.9 | -1.5% |